<DOC>
	<DOCNO>NCT00044031</DOCNO>
	<brief_summary>This study test whether G17DT Immunogen , administer combination chemotherapy , effective safe treatment pancreatic cancer .</brief_summary>
	<brief_title>Safety Efficacy G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine Treatment Advanced Pancreatic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Inclusion criterion : Clinical diagnosis pancreatic adenocarcinoma unsuitable pancreatic tumor resection Life expectancy least 3 month Functional status Karnofsky Index least 70 Exclusion criterion : Prior treatment chemotherapy , radiotherapy , anticancer immunotherapy Chronic use corticosteroid , except inhaled corticosteroid use asthma chronic obstructive pulmonary disease Immunodeficiency Bone marrow transplant within past year Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>G17DT</keyword>
	<keyword>gemcitabine</keyword>
</DOC>